This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Social Bookmarking   What's this?

COMS Report No. 4

The Collaborative Ocular Melanoma Study Group

Arch Ophthalmol. 1997;115(7):886-893.

Abstract
Objective
To describe the clinical characteristics and survival experience of a prospectively followed up group of patients with small choroidal melanoma.

Methods
The Collaborative Ocular Melanoma Study (COMS) is a set of clinical trials designed to compare the role of radiotherapy and enucleation in the treatment of medium and large-size choroidal melanoma. From December 1986 to August 1989, patients with small choroidal melanoma, not large enough to be eligible for the COMS clinical trials, were offered participation in a nonrandomized prospective follow-up study. Small choroidal melanomas were defined as 1.0 to 3.0 mm in apical height and at least 5.0 mm in basal diameter. A total of 204 patients were enrolled in the study. Patients were followed up annually through August 1989. Two additional assessments of treatment status and mortality were conducted in 1993-1994 and 1995-1996. The median length of follow-up was 92 months. Eight percent of patients were treated at the time of study enrollment and an additional 33% were treated during follow-up.

Results
Twenty-seven patients have died; 6 deaths were reported by the clinical center as due to metastatic melanoma. The Kaplan-Meier estimate of 5-year all-cause mortality was 6.0% (95% confidence interval, 2.7%-9.3%) and 8-year all-cause mortality was 14.9% (95% confidence interval, 9.6%-20.2%).

Conclusions
Otherwise healthy patients, average age of 60 years, without a previous diagnosis of malignant disease who have small choroidal lesions judged to be melanoma have a low risk of dying within 5 years.

Footnotes
Members of the writing team, who signed authorship responsibility, financial disclosure, and copyright transfer statements for the group are as follows: B. Michele Melia, ScM, Marie Diener-West, PhD, and Andrew P. Schachat, MD.

A complete list of the members of the Collaborative Ocular Melanoma Study (COMS) Group who participated in the Small Tumor Study appears on pages 892 and 893.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Evisceration After Complete Evaluation an Acceptable Option
Julian D. Perry, Craig D. Lewis, and Mark Levine
Arch Ophthalmol. 2009;127(9):1227-1228.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravascular Presence of Tumor Cells as Prognostic Parameter in Uveal Melanoma: A 35-Year Survey
Ly et al.
IOVS 2010;51:658-665.
ABSTRACT | FULL TEXT  

Evisceration After Complete Evaluation an Acceptable Option
Perry et al.
Arch Ophthalmol 2009;127:1227-1228.
FULL TEXT  

Genomic Typing of Uveal Melanoma--Reply
Robertson
Arch Ophthalmol 2009;127:114-115.
FULL TEXT  

Endoresection in high posterior choroidal melanomas: long-term outcome
Garcia-Arumi et al.
Br J Ophthalmol 2008;92:1040-1045.
ABSTRACT | FULL TEXT  

Cytogenetics in the Management of Uveal Melanoma: Are We There Yet?
Robertson
Arch Ophthalmol 2008;126:409-410.
FULL TEXT  

Reduced expression of autotaxin predicts survival in uveal melanoma
Singh et al.
Br J Ophthalmol 2007;91:1385-1392.
ABSTRACT | FULL TEXT  

The case for observational management of suspected small choroidal melanoma.
Murray and Sobrin
Arch Ophthalmol 2006;124:1342-1344.
FULL TEXT  

Long term ultrasonic follow up of choroidal naevi and their transformation to melanomas
Kaiserman et al.
Br J Ophthalmol 2006;90:994-998.
ABSTRACT | FULL TEXT  

HLA Class I and II Genotype in Uveal Melanoma: Relation to Occurrence and Prognosis
Maat et al.
IOVS 2006;47:3-6.
ABSTRACT | FULL TEXT  

Trends in Size and Treatment of Recently Diagnosed Choroidal Melanoma, 1987-1997: Findings From Patients Examined at Collaborative Ocular Melanoma Study (COMS) Centers: COMS Report No. 20
Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 2003;121:1156-1162.
ABSTRACT | FULL TEXT  

Tumor Basal Area and Metastatic Death After Proton Beam Irradiation for Choroidal Melanoma
Li et al.
Arch Ophthalmol 2003;121:68-72.
ABSTRACT | FULL TEXT  

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, II: Characteristics of Patients Enrolled and Not Enrolled: COMS Report No. 17
The Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 2001;119:951-965.
ABSTRACT | FULL TEXT  

Metastatic Melanoma Death Rates by Anatomic Site After Proton Beam Irradiation for Uveal Melanoma
Li et al.
Arch Ophthalmol 2000;118:1066-1070.
ABSTRACT | FULL TEXT  

Combination of Clinical Factors Predictive of Growth of Small Choroidal Melanocytic Tumors
Shields et al.
Arch Ophthalmol 2000;118:360-364.
ABSTRACT | FULL TEXT  

Transpupillary Thermotherapy as Primary Treatment for Small Choroidal Melanomas
Robertson et al.
Arch Ophthalmol 1999;117:1512-1519.
ABSTRACT | FULL TEXT  

Factors Predictive of Growth and Treatment of Small Choroidal Melanoma: COMS Report No. 5
The Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 1997;115:1537-1544.
ABSTRACT  

Small Choroidal Melanoma
Murray
Arch Ophthalmol 1997;115:1577-1578.
ABSTRACT